We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA, Industry Consider Disclosing Data From Pending, Withdrawn NDAs
FDA, Industry Consider Disclosing Data From Pending, Withdrawn NDAs
November 6, 2009
The agency may begin disclosing safety and efficacy data in pending and withdrawn NDAs after a report with recommendations on such disclosures is released early next year by the FDA Transparency Task Force.